Is a cannabinoid a substitute for CBT-I?

No. CBT-I has the strongest evidence base for chronic insomnia. Cannabinoids are considered when CBT-I has been attempted and has not delivered sustained improvement, or when CBT-I is not accessible to the patient.

Will cannabinoid therapy leave me drowsy the next day?

Some formulations can cause next-day somnolence. The doctor will discuss timing, dose, and impairment-risk — particularly if you drive or operate machinery. Balanced THC:CBD oils taken earlier in the evening often mitigate this better than late-night dosing.

How is tolerance managed?

Any medication for sleep, including cannabinoids, can develop tolerance with nightly use. Doctors typically build in scheduled review points and discuss intermittent dosing or planned breaks to limit this.

Is melatonin still useful alongside cannabinoid sleep therapy?

Often yes. Melatonin and cannabinoids work via different mechanisms (circadian-rhythm signalling vs endocannabinoid modulation), and combination is generally safe. The doctor will not stop your melatonin — they will assess whether the cannabinoid adds incremental sleep-quality benefit on top of what melatonin already provides.

What if I have sleep apnoea — does that change anything?

Yes. Untreated sleep apnoea must be addressed first — usually with CPAP — because cannabinoid-induced sedation can theoretically worsen apnoeic episodes. The doctor will ask about snoring, witnessed apnoeas, and daytime sleepiness; if there is a pre-test indication, they may defer cannabinoid initiation pending a sleep study.

Condition · ICD-11 7A00

Insomnia

Creator: Docto24 Clinical Team
Published: 2026-04-16

Reviewed by the Docto24 clinical team · Psychiatry · Last updated 16 Apr 2026 · Published 16 Apr 2026

Chronic insomnia is difficulty falling asleep, staying asleep, or waking too early — at least three nights per week for three months or longer — with daytime consequences. First-line management is cognitive behavioural therapy for insomnia (CBT-I), sleep hygiene review, and short-course conventional sleep medication under medical supervision. Cannabinoid-based therapy may be considered in South Africa under Section 21 when those measures have been trialled without sustained benefit, with explicit attention to any underlying mood or anxiety disorder driving the wakefulness.

What the evidence says

Evidence for cannabinoids in primary insomnia remains limited. Short-term trials suggest modest improvements in self-reported sleep quality and reductions in sleep-onset latency, particularly with balanced THC:CBD formulations, but heterogeneity between studies is high and long-term data is sparse. The American Academy of Sleep Medicine does not endorse cannabinoids as first-line for chronic insomnia. Cannabinoids are typically considered as adjunctive or second-line after CBT-I and sleep-hygiene review.

How the doctor will evaluate you

Expect questions about sleep onset, night-wake frequency, screen exposure, caffeine intake, alcohol, shift patterns, and any mood or anxiety symptoms. The doctor will look for untreated depression, anxiety, or sleep apnoea — treating the driver often resolves the insomnia without cannabinoid therapy. A formal sleep-diary over 7–14 days is commonly requested before a decision.

When to see a doctor urgently

Loud snoring, witnessed apnoeas, or daytime drowsiness suggesting sleep apnoea
Low mood, loss of interest, or suicidal ideation
Active substance-use concerns (including alcohol)
Personal or family history of psychosis or bipolar-I disorder
Driving or safety-critical occupation without prior discussion of impairment risk

If any of the above apply, seek in-person medical care — do not wait for a remote Section 21 consultation.

The South African Section 21 pathway

Insomnia is a less-common Section 21 indication than chronic pain, but it is assessed on the same case-by-case basis. The doctor must document why first-line options (CBT-I, sleep hygiene, short-course conventional medication) have been exhausted or are unsuitable. Authorisations are time-limited and reviewed at renewal.

Frequently asked

Is a cannabinoid a substitute for CBT-I?: No. CBT-I has the strongest evidence base for chronic insomnia. Cannabinoids are considered when CBT-I has been attempted and has not delivered sustained improvement, or when CBT-I is not accessible to the patient.
Will cannabinoid therapy leave me drowsy the next day?: Some formulations can cause next-day somnolence. The doctor will discuss timing, dose, and impairment-risk — particularly if you drive or operate machinery. Balanced THC:CBD oils taken earlier in the evening often mitigate this better than late-night dosing.
How is tolerance managed?: Any medication for sleep, including cannabinoids, can develop tolerance with nightly use. Doctors typically build in scheduled review points and discuss intermittent dosing or planned breaks to limit this.
Is melatonin still useful alongside cannabinoid sleep therapy?: Often yes. Melatonin and cannabinoids work via different mechanisms (circadian-rhythm signalling vs endocannabinoid modulation), and combination is generally safe. The doctor will not stop your melatonin — they will assess whether the cannabinoid adds incremental sleep-quality benefit on top of what melatonin already provides.
What if I have sleep apnoea — does that change anything?: Yes. Untreated sleep apnoea must be addressed first — usually with CPAP — because cannabinoid-induced sedation can theoretically worsen apnoeic episodes. The doctor will ask about snoring, witnessed apnoeas, and daytime sleepiness; if there is a pre-test indication, they may defer cannabinoid initiation pending a sleep study.

Related conditions

Glossary — terms used on this page

Quick definitions for terminology referenced above. Each links to a fuller entry.

Think this might apply to you? An HPCSA-registered doctor will review your case.

START ELIGIBILITY REVIEW

R500 consultation · R400 SAHPRA fee per product · 3–7 days end-to-end